BACKGROUND: Accelerated progression of hepatic fibrosis has been shown in patients co-infected with hepatitis C virus (HCV) and HIV. Liver fibrosis is a dynamic process in which the altered balance between matrix metalloproteinases (MMPs) and their specific inhibitors (TIMPs) may play a major role. METHOD: The involvement of MMP-9 and TIMP-1 in HCV liver disease progression in patients co-infected with HIV was evaluated. Plasma concentrations of human MMP-9 and TIMP-1 were assessed in 76 HIV-infected patients; 27 were co-infected with HCV and 49 were HCV negative. 18 healthy donors were included as controls. RESULTS: Patients with HIV infection exhibited a striking increase in TIMP-1 levels; this is more evident in patients with advanced CD4 depletion. There was no elevation in the plasma concentrations of the MMP-9. The highest levels of TIMP-1 were found in the HIV/HCV co-infected patients. The values of TIMP-1 in HIV-infected patients with chronic HCV hepatitis were significantly higher than in HIV-positive individuals without HCV infection, even including those with low CD4 count. No significant differences were seen in the MMP-9 levels. CONCLUSION: These findings suggest that the altered balance between circulating MMP-9 and TIMP-1 during HIV infection may play an important role in exacerbating liver fibrosis progression in patients co-infected with HCV.
BACKGROUND: Accelerated progression of hepatic fibrosis has been shown in patients co-infected with hepatitis C virus (HCV) and HIV. Liver fibrosis is a dynamic process in which the altered balance between matrix metalloproteinases (MMPs) and their specific inhibitors (TIMPs) may play a major role. METHOD: The involvement of MMP-9 and TIMP-1 in HCV liver disease progression in patients co-infected with HIV was evaluated. Plasma concentrations of humanMMP-9 and TIMP-1 were assessed in 76 HIV-infectedpatients; 27 were co-infected with HCV and 49 were HCV negative. 18 healthy donors were included as controls. RESULTS:Patients with HIV infection exhibited a striking increase in TIMP-1 levels; this is more evident in patients with advanced CD4 depletion. There was no elevation in the plasma concentrations of the MMP-9. The highest levels of TIMP-1 were found in the HIV/HCV co-infectedpatients. The values of TIMP-1 in HIV-infectedpatients with chronic HCV hepatitis were significantly higher than in HIV-positive individuals without HCV infection, even including those with low CD4 count. No significant differences were seen in the MMP-9 levels. CONCLUSION: These findings suggest that the altered balance between circulating MMP-9 and TIMP-1 during HIV infection may play an important role in exacerbating liver fibrosis progression in patients co-infected with HCV.
Authors: Alba Diaz; Felipe García; Anna Mozos; Miguel Caballero; Agathe León; Antonio Martinez; Cristina Gil; Montserrat Plana; Teresa Gallart; Jose M Gatell; Llúcia Alós Journal: J Infect Dis Date: 2011-03-15 Impact factor: 5.226
Authors: Melinda E Wilson; Filomena O Dimayuga; Janelle L Reed; Thomas E Curry; Carol F Anderson; Avindra Nath; Annadora J Bruce-Keller Journal: Endocrine Date: 2006-04 Impact factor: 3.633
Authors: Javed Butler; Andreas P Kalogeropoulos; Kevin J Anstrom; Priscilla Y Hsue; Raymond J Kim; Rebecca Scherzer; Sanjiv J Shah; Svati H Shah; Eric J Velazquez; Adrian F Hernandez; Patrice Desvigne-Nickens; Eugene Braunwald Journal: J Card Fail Date: 2018-03-02 Impact factor: 5.712
Authors: Changjiang Lei; Yao Yao; Bin Shen; Junru Liu; Qingyun Pan; Ning Liu; Lei Li; Jianbin Huang; Zhixiong Long; Liwei Shao Journal: Cancer Manag Res Date: 2019-09-23 Impact factor: 3.989
Authors: Tiziana Latronico; Maria Teresa Branà; Pasqua Gramegna; Anna Fasano; Gaetano Di Bari; Grazia Maria Liuzzi Journal: PLoS One Date: 2013-02-04 Impact factor: 3.240